A student observes a change in cancer during an experiment on cell communication. Which conclusion is most supported by this observation?

Core Concept

PILLAR 1 — MOLECULAR/CONCEPTUAL MECHANISM

Step-by-Step Analysis

Cancer emerges from accumulated failures in the molecular circuitry governing cell communication, signal transduction, and cell-cycle control. Under normal physiological conditions, a growth factor such as epidermal growth factor (EGF) binds the extracellular ligand-binding domain of the receptor tyrosine kinase (RTK) EGFR. This ligand–receptor interaction induces a conformational change in the receptor's intracellular kinase domain, triggering trans-autophosphorylation of specific tyrosine residues on the receptor's cytoplasmic tail. These phosphorylated tyrosines serve as docking sites for adaptor proteins—most notably GRB2—which recruit the guanine nucleotide exchange factor SOS. SOS catalyzes the exchange of GDP for GTP on the membrane-associated small GTPase RAS, converting RAS from its inactive GDP-bound state into its active GTP-bound conformation. Active RAS-GTP then initiates a phosphorylation cascade through RAF, MEK, and ultimately ERK, a mitogen-activated protein kinase that translocates into the nucleus and phosphorylates transcription factors driving the expression of cyclin D1 (CCND1). Cyclin D1 binds and activates cyclin-dependent kinases CDK4 and CDK6, which phosphorylate the retinoblastoma protein (pRB), releasing the transcription factor E2F and enabling transcription of S-phase genes required for DNA replication.

Why Other Options Are Wrong

This tightly regulated signaling architecture depends on multiple built-in termination mechanisms: GTPase-activating proteins (GAPs) such as NF1 accelerate RAS's intrinsic GTPase activity, hydrolyzing GTP back to GDP and shutting down the signal; protein tyrosine phosphatases dephosphorylate RTK residues; and the tumor suppressor p53 transcriptionally upregulates the CDK inhibitor p21 (CDKN1A) in response to DNA damage, halting cell-cycle progression at the G1/S checkpoint. When mutations alter any of these nodes—constitutively active RAS mutants locked in the GTP-bound state, amplification of HER2/ERBB2 receptors, deletion of p53 (TP53), or loss of pRB function—the result is sustained, ligand-independent proliferative signaling. The cell no longer requires an external growth factor cue to divide; it has effectively gone rogue, bypassing the communication checkpoints that normally tether division to organismal needs.

PILLAR 2 — STEP-BY-STEP LOGIC

The question stem establishes that a student is conducting an experiment specifically on cell communication and observes a change in cancer. This experimental framing is not incidental—it signals that the independent variable manipulates some component of a signaling pathway, and the dependent variable (the observed change in cancer) is a downstream consequence of perturbing that pathway. Because cancer is, at its molecular core, a disease of dysregulated cell communication, observing a change in cancer during a cell-communication experiment directly links the two phenomena. The disruption of normal cellular function refers precisely to the breakdown in ligand–receptor specificity, signal amplification fidelity, or feedback inhibition that characterizes oncogenic transformation. Furthermore, the phrase "may affect the organism" acknowledges a fundamental biological principle: multicellular organisms depend on the coordinated behavior of their constituent cells. When one cell population evades growth-suppressive signals transmitted via paracrine factors such as transforming growth factor-beta (TGF-β), ignores apoptotic cues mediated by Fas ligand binding to the Fas receptor, or secretes its own autocrine growth signals (as seen when tumor cells overproduce vascular endothelial growth factor, VEGF, to recruit blood vessels via angiogenesis), the entire organism suffers. Tumors compete with normal tissues for nutrients and oxygen, metastatic cells invade distant organs by breaking through basement membranes using secreted matrix metalloproteinases, and immune surveillance may be overwhelmed.

The correct answer, option A, captures this causal chain: the experiment targets cell communication, a disruption in that communication produces a cancer phenotype, and that phenotype has organismal consequences. The hedging language "may affect" is scientifically appropriate because not every cellular-level change scales to produce a detectable organismal phenotype—some mutations are corrected by DNA repair mechanisms, some aberrant cells are eliminated by cytotoxic T lymphocytes or natural killer cells, and some tumors remain benign.

PILLAR 3 — DISTRACTOR ANALYSIS

Option B claims the change is "likely due to random variation and has no biological significance." This distractor exploits a common student tendency to dismiss unexpected experimental results as noise rather than investigating their mechanistic basis. The critical flaw here is that cancer is not stochastic background variation—it represents a directed, clonal expansion of cells harboring specific mutations in genes encoding signaling proteins such as RAS, p53, or BRCA1. Dismissing a cancer phenotype as biologically insignificant ignores the entire framework of signal transduction dysregulation covered in Unit 4, where even a single amino acid substitution (for example, the G12V mutation in HRAS that prevents GAP-mediated GTP hydrolysis) can constitutively activate proliferative signaling and transform a normal fibroblast into a tumor cell.

Option C states that "the experimental conditions are irrelevant to the system." This option traps students who compartmentalize their knowledge and fail to integrate the experimental design with the biological outcome. The phrase is logically self-contradictory within the question's context: if a change in cancer is observed when cell-communication variables are manipulated, then those conditions are, by definition, relevant to the system being studied. A student who selects this option may be conflating controlled variables with irrelevant variables, failing to recognize that the experimental manipulation of signaling components (for instance, adding a competitive inhibitor of EGFR such as erlotinib) directly probes the relationship between communication and oncogenesis.

Option D asserts that "the change demonstrates that cancer is unrelated to cell communication." This is the most directly contradicted option given established molecular biology. Decades of research have established that oncogenes (EGFR, HER2, RAS, MYC) and tumor suppressors (TP53, RB1, PTEN) operate within or directly upon cell-communication and signal-transduction pathways. PTEN, for example, is a lipid phosphatase that dephosphorylates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), thereby terminating PI3K-AKT signaling; loss of PTEN function leads to constitutive AKT activation, promoting cell survival and proliferation independently of external growth signals. Selecting option D indicates a fundamental misunderstanding of the causal architecture linking cell communication to cancer, a relationship that is the central focus of multiple learning objectives within Unit 4.